Abstract
Background
Losartan is used for anti-proteinuric as well as blood pressure effects in chronic kidney disease (CKD). It is metabolized by cytochrome P450 (CYP) 2C9 to active E-3174. Single nucleotide polymorphisms in CYP2C9 that reduce catalytic activity could reduce clinical benefits.
Aim
The study aims were to determine whether CYP2C9 variant alleles (*2 and *3) altered urinary protein excretion, glomerular filtration rate, and blood pressure in Caucasian patients prescribed losartan.
Methods
Differences between baseline and 6-month follow-up outcomes were compared by CYP2C9 genotypes in 59 patients using unpaired t test or Mann–Whitney U test.
Results
Primary renal disease patients had a trend toward less favorable antiproteinuric response (−31.7 ± 156 vs. −125 ± 323%; p = 0.123) when carrying variant alleles. Patients with secondary renal diseases had less favorable diastolic blood pressure (9.8 ± 16.0 vs. −3.2 ± 10.6 mmHg; p = 0.043) and systolic blood pressure (16.2 ± 27.1 vs. −5.5 ± 17.5 mmHg; p = 0.044) with CYP2C9 variants.
Conclusion
These preliminary results suggest a possible influence of CYP2C9 genotype on proteinuria and blood pressure in Caucasian CKD patients treated with losartan.
References
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al (1995) Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123:754–762
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921–927
National Kidney Foundation (2007) KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49:S12–S154
Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429–439
Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–263
Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML et al (2001) Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051–1056
Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F et al (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89–98
DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA (2005) Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 315:1085–1090
Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K et al (2002) The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 20:2089–2093
Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK et al (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83:312–321
Michaud V, Vanier MC, Brouillette D, Roy D, Verret L, Noel N et al (2008) Combination of phenotype assessments and CYP2C9–VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther 83:740–748
Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP (1995) Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 23:285–289
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254
Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628–631
Lajer M, Tarnow L, Andersen S, Parving HH (2007) CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy. Diabet Med 24:323–325
Sarafidis PA, Khosla N, Bakris GL (2007) Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49:12–26
Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA (2003) Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 23:720–725
Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C et al (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286–296
Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO et al (2004) CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 60:337–342
Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R et al (2003) Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 59:589–592
Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B et al (2004) Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527–537
Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J et al (2003) Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26:1501–1506
Park HC, Choi HY, Kim BS, Kang SW, Choi KH, Ha SK et al (2006) Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism. Kidney Blood Press Res 29:216–224
Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J et al (2008) ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 19:771–779
Acknowledgments
We wish to thank Howard McLeod, PharmD for reviewing this manuscript.
Funding
This study was funded in part by the American College of Clinical Pharmacy - Merck Cardiovascular Fellowship (KDL), NIH 5K23DK64888 (MSJ), and the Intramural Research Program of the NIH and NIEHS (J.B. and J.A.G.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joy, M.S., Dornbrook-Lavender, K., Blaisdell, J. et al. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol 65, 947–953 (2009). https://doi.org/10.1007/s00228-009-0707-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-009-0707-7